Lucius Larotrectinib – Online kaufen
Lucius Larotrectinib – Online kaufen
Lucius Larotrectinib – Online kaufen

Lucius Larotrectinib – Online kaufen

EUR 147.33

2,900+ verkauft
Sonderpreis

Stationaere Apotheke in Hongkong, 100% Echtheitsgarantie

Wichtige Merkmale

In 2018, the FDA approved larotrectinib in the United States for tumors driven by NTRK1, NTRK2, or NTRK3 gene fusions. Use only as directed by a physician.

Servicegarantie

Grenzueberschreitender DirektversandZugelassene ApothekeDurch Apotheker geprueftEchtheitsgarantie

Spezifikationen

Spezifikation
100mg*30 Kapseln
Hersteller
Lucius Pharmaceuticals
Versand
Hongkong

10000 vorrätig

Kategorie: Marke:

Produktinformationen

Englischer Name
Larotrectinib
Generischer Name
Larotrectinib

Spezifikationen

Spezifikation
100mg*30 Kapseln
Hersteller
Lucius Pharmaceuticals
Versand
Hongkong

Ausfuehrliche Hinweise

Indikationen

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Wirkmechanismus

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Pharmakologie

12.1 Wirkweise (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Dosierung

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Vorsichtshinweise

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Wechselwirkungen

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosierung(2.5)] CYP3A4 ， ， [ Dosierung(2.5)]

Nebenwirkungen

Beschreibung [ Vorsichtshinweise(5.1)] [ Vorsichtshinweise(5.2)] [ Vorsichtshinweise(5.3)] 6.1 ， ， ， Vorsichtshinweise 444 VITRAKVI ， 62% 6 ，44% ……

Lagerung

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Package Insert

Ingredients

11 VITRAKVI C₂₁H₂₄F₂N₆O₆S， 526.51 g/mol， 428.44 g/mol (3S)-N-{5-[(2R)-2-(2,5- )-1- ] [1,5-a] -3- }-3- -1- ，

Indications

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Dosierung

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Nebenwirkungen

Beschreibung [ Vorsichtshinweise(5.1)] [ Vorsichtshinweise(5.2)] [ Vorsichtshinweise(5.3)] 6.1 ， ， ， Vorsichtshinweise 444 VITRAKVI ， 62% 6 ，44% ……

Precautions

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Use in Pregnancy and Lactation

8.1 ， TRK ， Wirkweise[ (12.1)]，VITRAKVI VITRAKVI ， ， ， 100 mg 11 0.7 ， ，

Wechselwirkungen

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosierung(2.5)] CYP3A4 ， ， [ Dosierung(2.5)]

Clinical Pharmacology

12 12.1 Wirkweise (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3 TRK ， ，

Clinical Studies

14 VITRAKVI ， NTRK LOXO-TRK-14001 (NCT02122913) SCOUT (NCT02637687) NAVIGATE (NCT02576431) ， ， VITRAKVI 100 mg， 18 VITRAKVI 100 mg/m²， ， 100 mg NTRK

Lagerung

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Produktbewertungen (15)

Filter: Alle Bewertungen
4.8★★★★★
15 Kundenbewertungen12 verifizierte Kaeufe
+o***e· 3周前
★★★★
+t***3· 1个月前
Verifizierter Kauf
★★★★★

Produktbeschreibung

Indikationen

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Wirkmechanismus

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Pharmakologie

12.1 Wirkweise (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Dosierung

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Vorsichtshinweise

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Wechselwirkungen

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosierung(2.5)] CYP3A4 ， ， [ Dosierung(2.5)]

Nebenwirkungen

Beschreibung [ Vorsichtshinweise(5.1)] [ Vorsichtshinweise(5.2)] [ Vorsichtshinweise(5.3)] 6.1 ， ， ， Vorsichtshinweise 444 VITRAKVI ， 62% 6 ，44% ……

Lagerung

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F